Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2016-05-09
Target enrollment:
Participant gender:
Summary
Patients will receive escalating doses of ldarubicin combined to Azacitidine given at the
FDA/EMEA approved Schedule and dosing.
For the Phase I study :
Determine the safety and tolerance of escalating doses of Idarubicin combined to Azacitidine
in patients with INT-2 or higher risk MDS.
For the phase II study:
Primary: Evaluate rate and duration of response (according to IWG 2006 criteria and IWG 2000
criteria) to the combination of Idarubicin and Azacitidine in patients with INT-2 or higher
risk MDS